This trial is evaluating whether Ibrutinib will improve 1 primary outcome and 7 secondary outcomes in patients with Relapse. Measurement will happen over the course of Up to 24 cycles (96 weeks).
This trial requires 208 total participants across 2 different treatment groups
This trial involves 2 different treatments. Ibrutinib is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"As stated, leukemia can result from a number of factors, such as genetics, exposure to certain chemicals and the environment, or exposure through medical treatment.\n" - Anonymous Online Contributor
"The estimated number of new cases of acute myeloid leukemia or acute lymphocytic leukemia will peak in 2016, reaching 1.7-3.6 million cases, respectively. The cumulative number of cases of AML or ALL will peak in 2018, reaching 4.3-4.9 million cumulative cases, respectively. However a substantial portion of these cases will be diagnosed during the first 5 years of adulthood, which could potentially delay treatment of people with leukemias. We recommend that the US Preventive Services Task Force recommends that people under the age of 50 receive screening for leukemia and recommend that the screening includes both peripheral blood and bone marrow tests." - Anonymous Online Contributor
"It is known that leukemia cannot be cured and remission is just a period with no signs of disease. However, patients can have a remission, which can extend the time they live before dying." - Anonymous Online Contributor
"This is the most common type of blood cancer which is a cancer of cells in the blood, bone marrow or other parts of the body. A single cell in the body may become cancerous; this is called leukemias, as they occur in the blood and are often called blood cancers. The leukemia is one of the most dangerous types of blood cancer, as there is no cure for it yet." - Anonymous Online Contributor
"In the past year, an increasing number of patients received allogeneic stem cell transplants as treatment for leukemia, especially chronic lymphocytic leukemia (CLL). Most common indications for autologous stem cell transplantations (ASCTs) in patients with CLL are as a part of frontline therapy, although they may be lifesaving. ASCT is the initial treatment option when there are a few weeks left to live. The aim of ASCT before the onset of a progression to refractory disease is to improve the patient prognosis. At the same time patients treated with allosensitizing agents such as alemtuzumab should be carefully observed in order to detect any potential treatment-related adverse events." - Anonymous Online Contributor
"Many people with leukemia have no obvious symptoms. In the United States, leukemia is the most common blood cancer. Other forms of blood cancer are typically detected through screening of high-risk populations such as individuals with family history of the disease, or people with certain heredity, such as BRCA1 genes. Symptoms and signs of leukemia are very common and may appear suddenly, with symptoms including fever, swollen lymph nodes, loss of appetite, anemia, vomiting, diarrhea, and a mass or blister on the surface of the skin. In addition to symptoms, signs can be identified at diagnosis by signs such as red and painful bumps (masses) throughout the body, and a change in the shape of the spleen or liver." - Anonymous Online Contributor
"A variety of factors contribute more than 10% to causation of adult leukemia. The genetic predisposition and/or environmental factors play a part in childhood leukemia. The environmental factors include: ionizing radiation, infections (HIV), metabolic, and dietary factors. Leukemia is diagnosed and treated differently depending on diagnosis. What is a diagnosis? There are different definitions of diagnosis, including the US Food and Drug Administration's definition. It is based on the ICD-10 and can be divided into five components based on: medical causes, anatomical or pathological findings, clinical courses, or laboratory markers as a means of classification." - Anonymous Online Contributor
"The following research is of interest to most doctors, as they often get asked for details about the disease's specific treatments, how to diagnose, how to prevent it or how to fight it, and who suffers most.\n" - Anonymous Online Contributor
"Overall, the average age the patient was diagnosed with leukemia in Poland is 59 years old. Median age is 58.5. The mean age of patients who survived was 66.5. Younger patients are under 50 years old and they are usually female (median age 56, mean age 57)." - Anonymous Online Contributor
"The odds of developing leukemia are highest if a person is a man, is younger than 45, has been or is currently overweight, has not had an acute illness during the preceding 12 months or has a family history of the disease. The odds of developing leukemia as an adult may increase if the person has been in the Navy for 12 months or in the Air Force for one year or more. The disease becomes less common as people age and the risk of developing leukemia decreases as does the risk of getting a bone marrow transplant from a relative." - Anonymous Online Contributor
"Ibrutinib is well tolerated at a dose of 50/mg twice per day, with an improved appetite, good quality of life and no significant changes in hematological parameters assessed at baseline, week 24 or 52. This finding is comparable to that previously reported regardless of first-line treatment (ibrutinib or CHOP plus rituximab). The low incidence of drug-related adverse effects is, as expected of an inhibitor of the protein Bruton's tyrosine kinase (Btk) and the protein phosphatase SHP-1/2, and is compatible with clinical development of ibrutinib." - Anonymous Online Contributor